Denali Therapeutics/$DNLI
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Ticker
$DNLI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
443
ISIN
US24823R1059
Website
DNLI Metrics
BasicAdvanced
$2.2B
-
-$2.67
1.33
-
Price and volume
Market cap
$2.2B
Beta
1.33
52-week high
$31.56
52-week low
$10.57
Average daily volume
1.6M
Financial strength
Current ratio
9.563
Quick ratio
8.921
Long term debt to equity
3.567
Total debt to equity
4.332
Interest coverage (TTM)
-1,030.41%
Profitability
EBITDA (TTM)
-513.951
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-22.58%
Return on equity (TTM)
-35.21%
Valuation
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-6.587
Free cash flow yield (TTM)
-15.18%
Free cash flow per share (TTM)
-226.20%
Growth
Earnings per share change (TTM)
173.65%
3-year earnings per share growth (CAGR)
4.47%
What the Analysts think about DNLI
Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.
Bulls say / Bears say
Denali Therapeutics has completed the rolling submission of a Biologics License Application (BLA) for tividenofusp alfa, targeting Hunter Syndrome, indicating potential for future revenue growth upon approval. (finviz.com)
The company maintains a strong cash position with approximately $1.05 billion in cash, cash equivalents, and marketable securities as of March 31, 2025, providing financial stability for ongoing research and development. (finviz.com)
Analysts have maintained a 'buy' rating on Denali Therapeutics, with price targets ranging from $29 to $42, reflecting confidence in the company's growth prospects. (marketscreener.com)
Denali Therapeutics reported a quarterly adjusted loss of 78 cents per share for Q1 2025, missing analyst expectations of a 69-cent loss, which may raise concerns about profitability. (tradingview.com)
The company reported zero revenue for the quarter ended March 31, 2025, falling short of analyst expectations of $1.05 million, indicating potential challenges in revenue generation. (tradingview.com)
Insider selling activity, including a director selling over $678,000 in company stock, may signal a lack of confidence in the company's near-term prospects. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
DNLI Financial Performance
Revenues and expenses
DNLI Earnings Performance
Company profitability
DNLI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Denali Therapeutics stock?
Denali Therapeutics (DNLI) has a market cap of $2.2B as of July 04, 2025.
What is the P/E ratio for Denali Therapeutics stock?
The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of July 04, 2025.
Does Denali Therapeutics stock pay dividends?
No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Denali Therapeutics dividend payment date?
Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Denali Therapeutics?
Denali Therapeutics (DNLI) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.